Geron
17:59 :
Geron exec leaves with severance, consulting deal -
Jane Lebkowski, one of four Geron Corp. executives to pull down six-figure bonuses late last month, left the company Dec. 31 with $368,500 in severance pay, 12 months of health care coverage and an extension on exercisable stock options. ...
17:57 :
Four Geron execs split $600,000 in cash bonuses -
Geron Corp., which last month pulled out of the stem cell business, awarded four executives more than $600,000 in cash bonuses. The Menlo Park-based company (NASDAQ: GERN) said President and Chief Financial Officer David Greenwood was awarded ...
12:44 :
Geron halts stem cell work, cuts 38% of workforce -
Geron Corp., the company that was conducting the first U.S.-authorized trial of human embryonic stem cells, is ending the program to focus on its cancer drugs. The Menlo Park company will eliminate 66 full-time jobs, or...
19:58 :
Stem cell pioneer Geron to focus on cancer, cut 66 jobs -
Pioneering stem cell drug developer Geron Corp. said it will axe 66 jobs, halt its stem cell R&D programs and seek buyers for those assets. The Menlo Park company (NASDAQ: GERN) said it will concentrate on cancer treatments that could produce ...
19:21 :
Geron halting stem cell research, laying off staff -
MENLO PARK, Calif. (AP) -- Money troubles have forced the first company doing a government-approved test of embryonic stem cell therapy to discontinue further stem cell programs and lay off much of its staff....
00:37 :
Geron Names John Scarlett as CEO -
Geron Corp (GERN.O), which is conducting the first U.S.-approved human embryonic stem cell trial, has named John Scarlett as its chief executive officer, replacing interim CEO David Greenwood, who will leave the biotech company at the end ...
actualidad Geron -